NCT04299945 Effects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease
| NCT ID | NCT04299945 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of British Columbia |
| Condition | Interstitial Lung Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-08-07 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2024-08-07 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Exercise training as part of a structured pulmonary rehabilitation program is a key factor in improving quality of life and symptoms in people with interstitial lung disease (ILD). Optimal methods of exercise training are yet to be explored in ILD. Drinking beetroot juice, which is rich in nitrate, has been shown to improve exercise performance in a variety of groups, but its effects in ILD have not been tested. The purpose of this study is to determine if drinking nitrate-rich beetroot juice can improve exercise performance compared to drinking nitrate-free beetroot juice in people with ILD.
Eligibility Criteria
Inclusion Criteria: * A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses * Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis * Oxygen saturation ≥92% by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks * Can fluently read and write in English Exclusion Criteria: * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) (see Table 4 from ERS/ATS consensus statement) * Other significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * FVC \<50% or DLCO \<25% * Use of prednisone \>10 mg/day for \>2 weeks within 3 months of the first study visit * Cardiac pacemaker or any metal or electronics inside of the body
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04299945 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Interstitial Lung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04299945 currently recruiting?
Yes, NCT04299945 is actively recruiting participants. Contact the research team at Olivia.Ferguson@hli.ubc.ca for enrollment information.
Where is the NCT04299945 trial being conducted?
This trial is being conducted at Vancouver, Canada, Vancouver, Canada.
Who is sponsoring the NCT04299945 clinical trial?
NCT04299945 is sponsored by University of British Columbia. The trial plans to enroll 15 participants.